Log in

Relevant bibliographies by topics / EGFR / Books

Books on the topic 'EGFR'

To see the other types of publications on this topic, follow the link: EGFR.

Author: Grafiati

Published: 4 June 2021

Last updated: 6 July 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 books for your research on the topic 'EGFR.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse books on a wide variety of disciplines and organise your bibliography correctly.

1

Haley, John D., and William John Gullick, eds. EGFR Signaling Networks in Cancer Therapy. Totowa, NJ: Humana Press, 2008. http://dx.doi.org/10.1007/978-1-59745-356-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Cappuzzo, Federico. Guide to Targeted Therapies: EGFR mutations in NSCLC. Cham: Springer International Publishing, 2014. http://dx.doi.org/10.1007/978-3-319-03059-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

D, Haley John, and Gullick William John, eds. EGFR Signaling Networks in Cancer Therapy / edited by John D. Haley, William John Gullick. New York, NY: Humana Press, 2008.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

Rudzik, Nicholas James. A genetic analysis of the role of neuralized in the notch and EGFR pathways of Drosophila melanogaster. Ottawa: National Library of Canada, 1999.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

Saki, Mohammad. Radiolabeling of anti-EGFR antibody, Cetuximab, overcomes the radiotherapy resistance of Cetuximab resistant head and neck cancer cells. [S.l: s.n.], 2014.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

Faber, Anthony. Overcoming Resistance to EGFR Inhibitors in EGFR Mutant NSCLC. Elsevier Science & Technology, 2022.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

Faber, Anthony. Overcoming Resistance to EGFR Inhibitors in EGFR Mutant NSCLC. Elsevier Science & Technology Books, 2021.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

Patel, Harun M., Rahul Pawara, and S. J. Surana. Third-Generation EGFR Inhibitors: Overcoming EGFR Resistance and Toxicity Problems. Elsevier, 2018.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

Patel, Harun M., Rahul Pawara, and Sanjay J. Surana. Third Generation EGFR Inhibitors: Overcoming EGFR Resistance and Toxicity Problems. Elsevier, 2018.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

Schaeybroeck, Sandra Van. Egfr Activity As a Determinant of Response to Egfr-targeted Therapy. Leuven Univ Pr, 2006.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

11

Third Generation EGFR Inhibitors. Elsevier, 2019. http://dx.doi.org/10.1016/c2017-0-02893-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Cappuzzo, Federico. Guide to Targeted Therapies : EGFR mutations in NSCLC: EGFR mutations in NSCLC. Adis, 2014.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

13

Haley, John D., and William John Gullick. EGFR Signaling Networks in Cancer Therapy. Humana, 2011.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

14

Haley, John D., and William John Gullick. EGFR Signaling Networks in Cancer Therapy. Humana Press, 2009.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

15

Cappuzzo, Federico. Guide to Targeted Therapies: EGFR Mutations in NSCLC. Springer, 2014.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

16

Cappuzzo, Federico. Guide to Targeted Therapies: Egfr Mutations in Nsclc. Springer International Publishing AG, 2014.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

17

Hu, Shi. Novel Sensitizing Agents for Therapeutic Anti-EGFR Antibodies. Elsevier Science & Technology, 2022.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

18

Hu, Shi. Novel Sensitizing Agents for Therapeutic Anti-EGFR Antibodies. Elsevier Science & Technology Books, 2022.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

19

Herrington, William G., Aron Chakera, and Christopher A. O’Callaghan. Chronic kidney disease. Edited by Patrick Davey and David Sprigings. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199568741.003.0163.

Full text

Abstract:

Chronic kidney disease (CKD) is defined as abnormalities of kidney structure or function, where the abnormalities have been present for >3 months and have implications for health. It is characterized by a reduced estimated glomerular filtration rate (eGFR) or other renal abnormalities. CKD is staged according to the eGFR or the degree of albuminuria. The KDIGO (Kidney Disease: Improving Global Outcomes) criteria for CKD is either an eGFR that is <60 ml/min 1.73 m−2 and has been present for >3 months, or one or more markers of kidney damage, when these have been present for >3 months.

APA, Harvard, Vancouver, ISO, and other styles

20

Ahn, Sun-Young Sarah. The involvement of EGF, EGFr, MSX1, PAX9 and LEF1 in EL mouse third molar hypodontia. 2004.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

21

Troncone, Giancarlo, Julia Rotow, Parneet Cheema, and Pasquale Pisapia. Fast Facts: EGFR Exon 20 Insertion Mutations in NSCLC. Karger AG, S., 2022.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

22

Morris, Zachary Scott. Regulation of EGFR by the NF2 tumor supressor, Merlin. 2009.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

23

Troncone, Giancarlo, Julia Rotow, Parneet Cheema, and Pasquale Pisapia. Fast Facts: EGFR Exon 20 Insertion Mutations in NSCLC. Karger AG, S., 2022.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

24

Birle, Diana C. Interactions between inhibitors of mTOR and EGFR/ERK signaling in SiHa cervical carcinoma. 2004.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

25

Viloria-Petit, Alicia. The role of VEGF in tumor angiogenesis induced by EGFR-type oncogenic tyrosine kinases. 2003.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

26

D. Carlos L. Morales Gutiérrez. Valor Pronóstico Del Ca 19,9 y el Egfr Tisulares en la Supervivencia Del Carcinoma Colorrectal. Universidad Complutense de Madrid, Servicio de Publicaciones, 2005.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

27

Hodgkiss, Andrew. Introduction to cancer biology. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780198759911.003.0001.

Full text

Abstract:

A brief introduction to cancer biology, aimed at psychiatrists, is offered. Selective DNA transcription, the cell cycle, receptor tyrosine kinases, and cell signalling pathways are introduced, using the EGFR/RAS/MAPK pathway as an exemplar. The molecular pathology of oncogenesis is summarized, including discussion of oncogenes, tumour suppressor genes, and examples of driver mutations. The exploitation of such mutations in stratified medicine, using molecularly targeted agents, is mentioned. Finally, Hanahan and Weinberg’s six hallmarks of cancer are listed, adding angiogenesis and metastasis to the picture of oncogenesis.

APA, Harvard, Vancouver, ISO, and other styles

28

Bordás, Veronica. Development and analysis of a mathematical model integrating TGFα-EGFR trafficking and MAPK signaling in A431 cells. 2010.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

29

Preusser, Matthias, Gabriele Schackert, and Brigitta G. Baumert. Metastatic brain tumours. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199651870.003.0019.

Full text

Abstract:

Brain metastasis is a common clinical challenge in cancer patients, particularly those with lung cancer, breast cancer, and melanoma. The prognosis is poor, with median overall survival times measured in months for most patient populations. Established treatments include neurosurgical resection, radiotherapy (including stereotactic radiosurgery and stereotactic radiotherapy, whole-brain radiotherapy, and new radiation techniques), and supportive care measures. Recently, more and more targeted therapies such as EGFR inhibitors, HER2 antagonists, BRAF inhibitors, ALK inhibitors, and immune checkpoint inhibitors are demonstrating some efficacy in brain metastasis patients and should be considered in the clinical setting.

APA, Harvard, Vancouver, ISO, and other styles

30

Waldek, Stephen. Fabry disease. Edited by Neil Turner. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199592548.003.0338_update_001.

Full text

Abstract:

Fabry disease is a rare X-linked lysosomal storage disorder in which deficiency of alpha-galactosidase A leads to accumulation of substrate, mostly globotriaosylceramide (Gb3), which causes a progressive, multiorgan disease affecting predominantly the kidneys, skin, heart, and nervous system. Painful peripheral (‘acral’) neuropathy is characteristic. Proteinuria and estimated glomerular filtration rate (eGFR) are strongly associated with risk of progression, but this may be reduced by treatment with angiotensin-converting enzyme inhibitors as well as by enzyme replacement therapy (ERT). ERT was approved in 2001; it improves pain and other neuropathic symptoms, and well-being, and has been proven to clear deposits of Gb3 from tissues, at variable speeds. There is limited randomized controlled trial data but protective effects have been proven for renal outcomes, death, and better outcomes in some other organ systems. Renal function may be protected if ERT is commenced before there is heavy proteinuria or substantial loss of GFR. It is recommended to start ERT as soon as the diagnosis is made in those with very low or absent enzyme. For those with intermediate levels it is recommended to commence treatment only when signs or symptoms appear. Proteinuria and eGFR give most information from a renal point of view, but renal biopsy is also useful for confirming the renal diagnosis and staging the disease as well as monitoring progress in selected cases. Management should include regular screening for complications including myocardial and neurological assessments. It is likely that registries will show progressive rises in median survival with this condition.

APA, Harvard, Vancouver, ISO, and other styles

31

Smith, David J. Eger... Kirmizi Kedi, 2016.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

32

Ede D. Szabó Ottó Kaiser. Eger. Kaiser Art Ltd., 2003.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

33

n/a and Alper Akcam. Eger. Tekin Yayinevi, 2015.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

34

Güner, Hafize Çinar. Eger. Nesin Yayinevi, 2021.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

35

Denyer-Green, Barry. EGLR 1994. Estates Gazette, 1995.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

36

Eglr 2008. Estates Gazette, 2008.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

37

Denyer-Green, Barry. EGLR 2004. Estates Gazette, 2005.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

38

Denyer-Green, Barry. EGLR 1993. Estates Gazette, 1994.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

39

Denyer-Green, Barry. EGLR 2004. Estates Gazette, 2004.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

40

Denyer-Green, Barry. EGLR 1993. Estates Gazette, 1993.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

41

Forman, Gayle. Eger Yasarsam. Pegasus, 2013.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

42

Denyer-Green, Barry. EGLR 1992. Estates Gazette, 1993.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

43

Watt, J. Muir. EGLR 1979. Estates Gazette, 1995.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

44

Watt, J. Muir. EGLR 1978. Estates Gazette, 1995.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

45

Watt, J. Muir. EGLR 1975. Estates Gazette, 1995.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

46

Ubhi, Navjit, and Barry Denyer-Green. EGLR 2004. Estates Gazette, 2005.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

47

Denyer-Green, Barry. EGLR 2002. Estates Gazette, 2002.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

48

Denyer-Green, Barry. EGLR 2003. Estates Gazette, 2003.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

49

Denyer-Green, Barry. EGLR 2002. Estates Gazette, 2002.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

50

Denyer-Green, Barry. EGLR 1993. Estates Gazette, 1994.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!